Please login to the form below

Not currently logged in
Email:
Password:

GVHD

This page shows the latest GVHD news and features for those working in and with pharma, biotech and healthcare.

CHMP delays decision on Kiadis’ GVHD immunotherapy

CHMP delays decision on Kiadis’ GVHD immunotherapy

ATIR101 aims to target this, more specifically Graft-versus-Host-Disease (GVHD) along with cancer relapse. ... The T-cells that would normally cause GVHD are depleted from the donor lymphocytes using Kiadis Pharma’s photodepletion technology,

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics